Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects.

NCT05421078 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT05421078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05421078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects.
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2022
Completion date
April 21, 2023
Enrollment
102 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, high cholesterol, hypercholesterolemia